Stage
Reverse Merger | IPOTotal Raised
$66.01MAbout Aerpio Therapeutics
Aerpio Therapeutics is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of hypoxia-inducible factor 1α (HIF‐1α). The Company's lead program, AKB‐9778, is a first‐in‐class stabilizer of the Tie2 pathway and is in clinical development for diabetic macular edema.
Aerpio Therapeutics Headquarters Location
9987 Carver Road Suite 420
Cincinnati, Ohio, 45242,
United States
513-985-1920
Expert Collections containing Aerpio Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aerpio Therapeutics is included in 2 Expert Collections, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Diabetes
1,750 items
Aerpio Therapeutics Patents
Aerpio Therapeutics has filed 66 patents.
The 3 most popular patent topics include:
- Diseases of the eye and adnexa
- Disorders of choroid and retina
- Ophthalmology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/22/2016 | 3/23/2021 | Diseases of the eye and adnexa, Glaucoma, Eye surgery, Ophthalmology, Amines | Grant |
Application Date | 9/22/2016 |
|---|---|
Grant Date | 3/23/2021 |
Title | |
Related Topics | Diseases of the eye and adnexa, Glaucoma, Eye surgery, Ophthalmology, Amines |
Status | Grant |
Latest Aerpio Therapeutics News
Aug 17, 2018
17:42 EDT 17 Aug 2018 | BioPortfolio Reports Summary Aerpio Therapeutics Inc Aerpio is a biopharmaceutical company that develops novel monoclonal antibodies and small molecules. The company's programs include a Tie2 activator for diabetic macular edema and a hypoxiainducible factor stabilizer for the treatment of inflammatory bowel disease. Its HIF1a program comprises AKB4924 for wound healing and the treatment of inflammatory bowel diseases. Aerpio's products are used for the treatment of vascular diseases and improvement in wound healing. Its Novel HPTP Inhibitor is used to stabilize blood vessels for prevention of vascular leak and pathologic angiogenesis. Aerpio is headquartered in Cincinnati, Ohio, the US. Aerpio Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Where is Aerpio Therapeutics's headquarters?
Aerpio Therapeutics's headquarters is located at 9987 Carver Road, Cincinnati.
What is Aerpio Therapeutics's latest funding round?
Aerpio Therapeutics's latest funding round is Reverse Merger.
How much did Aerpio Therapeutics raise?
Aerpio Therapeutics raised a total of $66.01M.
Who are the investors of Aerpio Therapeutics?
Investors of Aerpio Therapeutics include Aerpio Pharmaceuticals, Novartis Venture Funds, Venture Investors, Triathlon Medical Venture Partners, Athenian Venture Partners and 7 more.
Who are Aerpio Therapeutics's competitors?
Competitors of Aerpio Therapeutics include Audentes Therapeutics.
You May Also Like
AAVLife, registered in Paris, is a privately held company dedicated to advancing gene therapy for rare diseases. AAVLife's lead indication is for Friedreich's Ataxia Cardiomyopathy. Its program is based on the successful use of a gene-therapy approach in a mouse model developed to mimic the gene defect and cardiac symptoms of Friedreich's Ataxia. The approach made use of an adeno-associated virus (AAV) to introduce a normal gene into cardiac tissue. The therapy restored cardiac function and reversed pathological heart enlargement in mice that had already progressed to heart failure.
Renova Therapeutics is a San Diego-based biopharmaceutical company and an industry leader in gene therapy, pursuing the development of treatments for congestive heart failure (CHF) and other chronic diseases. CHF is the most rapidly growing cardiovascular disorder in the United States, with an estimated six million people afflicted and 550,000 new cases diagnosed every year. Approximately 26 million patients have CHF worldwide. Renova Therapeutics, in a Public-Private Partnership with the National Institutes of Health, is currently supporting a Phase I/II trial of its novel lead therapy for patients with severe CHF (Class II, III and IV). This initial product is a single-dose gene therapy that, in animal studies, has shown substantially improved, sustained outcomes in heart failure models by safely and significantly improving myocardial function. The product is being evaluated for its safety and initial efficacy in a 3:1 randomized, double-blinded, placebo-controlled dose-ranging study involving 56 patients across seven US medical centers.
StrideBio is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies. The company is building a proprietary therapeutic pipeline focused on rare diseases.
Evive Biotech is an integrated biotech company developing therapeutic biologics. Products under development are mainly aimed at unsolved medical problems, such as oncology, inflammation, and autoimmune diseases. The company was formerly known as Generon Biomed, Inc. and changed its name to Evive Biotech in June 2020. The company was founded in 2004 and is based in Singapore, Singapore.
AGTC (NASDAQ: AGTC) is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology.
Calimmune is a clinical-stage biotechnology company focused on developing novel gene therapies that have the potential to improve and protect the lives of patients by enhancing their immune systems. Calimmune's lead product candidate for HIV, now in Phase I/II studies, is being evaluated as a one-time treatment to prevent HIV progression to AIDS. Calimmune is developing a full product pipeline of therapeutic candidates to address the unique needs of individuals at different stages of HIV infection and with various treatment histories.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.